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Sarcomas represent a clinically and biologically diverse group of malignant connective
tissue tumors. Despite aggressive conventional therapy, a large proportion of sarcoma
patients experience disease recurrence which will ultimately result in mortality. The pres-
ence of a unique population of cells, referred to as cancer stem cells (CSCs), have been
proposed to be responsible for refractory responses to current chemotherapies as well
underlying the basis for metastasis and relapse of disease – clinical corollaries to what has
been termed the CSC hypothesis.The presence of CSCs have been suggested in a variety
of hematologic and solid malignancies, and only more recently in sarcomas. Based on our
current understanding of normal stem cell biology and evidence obtained from the study
of malignant hematopoietic and solid tumors, researchers have identified candidate cell
surface markers (CD133, CD117, Stro-1), biochemical markers (aldehyde dehydrogenase
activity), and cytological characteristics (side population and spherical colony formation)
that may identify putative sarcoma CSCs. In this review, we explore the current state
of evidence that may suggest the existence of sarcoma CSCs. We present research in
osteosarcoma, the Ewing’s sarcoma family of tumors, rhabdomyosarcoma, as well as other
sarcoma subtypes to describe commonly used molecular and biochemical markers, as
well as techniques, used in the identification, isolation, and characterization of candidate
sarcoma CSCs. We will also discuss the current controversies and challenges that face
research in sarcoma CSC.
Keywords: sarcoma, cancer stem cell, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, aldehyde
dehydrogenase, side population, sphere formation
INTRODUCTION
Sarcomas are a biologically and clinically heterogeneous group of
malignant connective tissue tumors originating from mesenchy-
mal or ectodermal tissue. Sarcomas clinically span the entire age
spectrum with an annual incidence ranging from 1 to 6 per 100,000
persons, and comprising 1.5% of all malignant tumors in adults
and up to 8% in children. The categorization of different sarcoma
types have classically been based upon the histological resem-
blance of a given sarcoma subtype to the adult tissue which it
most closely resembles. There are currently over 50 sarcoma sub-
types described underscoring the clinical and biologic diversity
of this group of malignant cancers. Despite conventional multi-
modality treatment approaches (surgery, radiation therapy, and
chemotherapy), patients diagnosed with sarcoma experience dis-
proportionally higher rates of morbidity and mortality compared
to patients with other cancers. Long term survival rates average
∼50% in adults and up to 70% in children, but a significant
proportion suffer recurrence and dissemination of disease despite
aggressive therapy with subsequent rates of survival no higher than
20%. Investigations into the biology of cancer resistance to ther-
apy and cancer relapses despite initial remission of disease have
resulted in the development of a cell model that may account for
observed cancer treatment failures and disease recurrences – the
cancer stem cell (CSC) hypothesis.
In this review, the CSC hypothesis is discussed in terms of how it
may contribute to investigations exploring the origins of sarcomas.
We will also discuss methodologies utilized to characterize and
isolate so-called sarcoma CSCs and evaluate the evidence to sup-
port the existence of sarcoma CSCs in different sarcoma subtypes.
CANCER STEM CELL HYPOTHESIS
Malignant tumors, like the normal tissues from which they arise,
are composed of diverse cell populations. Within any given normal
tissue reside a subpopulation of cells with the distinct ability to self-
renew and are imbued with the ability to give rise to more differen-
tiated progenitor cells – the tissue stem cell. Similarly, a malignant
tumor is composed of a heterogeneous population of cells with
different degrees of differentiation, proliferation, and tumorigenic
potential. A subset of these cells, termed the CSC, possesses the
ability to self-renew and generate the diversity of cancer cells that
constitute the malignant tumor reminiscent of the tissue stem cell.
The hypothesis that CSCs lie at the apex of a cellular hierarchy
wherein the CSC gives rise to distinct populations of tumorigenic
and non-tumorigenic cells has evolved over the past decade and has
uncovered complex models that seek to account for the phenotypic
and functional heterogeneity of tumors (Magee et al., 2012).
In order to facilitate and enable the comparison and trans-
lation of data between different investigators working on cells
derived from similar or divergent tissues, a consensus defini-
tion of CSCs will be essential. One definition proposed for CSCs
is a cell contained within a tumor with the ability to: (1) self-
renew, and (2) possesses the ability to generate the heterogeneous
cell lineages which will constitute a tumor (Clarke et al., 2006).
Thus, reminiscent of the self-renewal properties of a tissue stem
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cell, CSCs can undergo self-renewal through symmetric division
to give rise to two identical daughter cells which maintain the
parental phenotype and capacity for self-renewal, or can alterna-
tively undergo asymmetric division to give rise to a self-renewing
daughter cell and a second more differentiated cell (transit ampli-
fying cell). It is further division and subsequent lineage commit-
ment and differentiation of this latter type of cell that ultimately
comprises the tumor bulk.
The origin of CSCs continues to be an area of considerable
uncertainty and debate in sarcomas. The term “CSC” has been
interpreted to imply that the CSC may originate from normal
tissue stem cells that acquire genetic and epigenetic changes con-
ferring a malignant, tumorigenic phenotype (Nowell, 1976; Clarke
et al., 2006; Baylin and Jones, 2011). However, it is important
to note that even within a cellular hierarchy, CSCs may arise
from either tissue stem cells or more differentiated cells that have
acquired stem cell-like properties during malignant transforma-
tion. The cells that comprise a given tumor may then undergo
a process of clonal evolution that gives rise to different sub-
populations of cells with variable biologic properties as a result
of selection pressure influenced by the genetic and epigenetic
changes acquired by the parental CSC. Although this view rep-
resents one possible hypothesis for the origin of the CSC and the
development of tumor heterogeneity, this model has neither been
definitively established nor does it necessarily apply to all tumors.
Indeed alternative CSC models have described the importance of
the tumor microenvironment in influencing the development of
heterogeneous populations of CSC-derived tumor cells (Polyak
et al., 2009; Charles et al., 2010; Bissell and Hines, 2011). Further-
more, the previously held understanding that the CSC is a rare
subset of cells within a given tumor and that the development of
tumorigenic and non-tumorigenic subpopulations of cells from a
parental CSC is unidirectional has been recently revised (Quintana
et al., 2010; Chaffer et al., 2011; Gupta et al., 2011). Evolution of the
CSC hypothesis which incorporates the tumor microenvironmen-
tal influences and the potential for bidirectional interconversion
of tumor cells between tumorigenic and non-tumorigenic pheno-
types have added to the challenge in identifying a CSC population
in sarcomas and will require improved understanding into the
origin of the numerous sarcoma subtypes and the application
of sophisticated techniques to identify, isolate, and characterize
putative sarcoma CSCs (Trucco and Loeb, 2012).
ISOLATION AND CHARACTERIZATION OF SARCOMA CANCER
STEM CELLS
Work involving the isolation and characterization of tissue stem
cells has resulted in the identification of biologic markers and the
development of techniques that have also been employed to isolate
and characterize CSCs. In this section, we will review the molec-
ular markers and techniques that enable investigators to identify,
isolate, and characterize putative sarcoma CSCs (summarized in
Table 1).
DESCRIPTIVE CANCER STEM CELL ASSAYS
Cell surface markers
The identification of cell surface markers that are specific to CSCs
would be invaluable to the prospective identification and isolation
Table 1 | Methodologies for characterizing sarcoma stem cells.
Sarcoma subtype Stem cell markers and assays
Osteosarcoma CD133
CD117/Stro-1
Side population/dye efflux
ALDH
Sphere formation
Ewing’s sarcoma family of tumors CD133
ALDH
Side population/dye efflux
Sphere formation
Rhabdomyosarcoma CD133
Sphere formation
Synovial sarcoma CD133
Side population/dye efflux
Liposarcoma CD133
ALDH
Fibrosarcoma ALDH
Chondrosarcoma CD133
Malignant fibrous histiocytoma (MFH;
pleomorphic undifferentiated sarcoma)
Side population/dye efflux
of CSCs particularly since CSCs may sometimes, but not always,
constitute a minute subpopulation of cells within a given tumor.
Important features of a CSC cell surface markers would have to not
only be specific to the CSC, but also should discriminate the CSC
from non-CSC cells within the tumor and ideally not expressed
by non-transformed, normal tissue cells. One of the first exam-
ples of a specific CSC cell surface marker was identified in acute
myeloid leukemia (AML) cells (Lapidot et al., 1994). Subsequent
work by numerous investigators have identified several other can-
didate CSC cell surface markers (e.g., CD34, CD44, CD90, CD117,
CD133, CD20) in a variety of different solid tumors including
brain, breast, prostate, melanoma, colon, lung, liver, and sarcomas
(Al-Hajj et al., 2003; Singh et al., 2003; Collins et al., 2005; Fang
et al., 2005; Eramo et al., 2008; Tirino et al., 2008).
A growing body of literature has described the cell surface
marker CD133 as a putative CSC surface marker. CD133 is five-
transmembrane domain protein encoded by the PROM1 gene
which was first recognized as a novel antigen on CD34+ prog-
enitor hematopoietic stem cells. Subsequent work revealed that
CD133 was also expressed on other normal human cells and tissues
including brain, kidney, prostate, pancreas, liver, colon, stomach,
uterus, and mammary glands (Mizrak et al., 2008; Wu and Wu,
2009). Research in brain tumors, followed by subsequent work
in other solid tumors, revealed that the CD133+ subpopulation
of cells were capable of recapitulating the parental tumor when
the CD133+ cells were transplanted into immunodeficient mice
(Singh et al., 2003, 2004; Suetsugu et al., 2006; Hermann et al.,
2007; Klein et al., 2007; Monzani et al., 2007; Ricci-Vitiani et al.,
2007; Eramo et al., 2008). These results suggest that CD133 may
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be useful for the identification of sarcoma CSCs. However, work
in colon and brain cancers has revealed that CD133− cells were
also able to give rise to tumors suggesting that CD133 positivity as
a specific marker for CSCs may not be valid for all solid tumor or
sarcoma subtypes (Ogden et al., 2008; Shmelkov et al., 2008; Wang
et al., 2008). Prospective validation of CD133 positivity as a marker
for sarcoma CSCs in other sarcoma subtypes would need to be per-
formed in the future and perhaps be combined with other assays
for the identification and isolation of putative sarcoma CSCs.
Stem cell gene expression
The pluripotent and self-renewal properties of embryonic stem
cells and the derived tissue stem cells are maintained by the expres-
sion of a multitude of genes that have been collectively termed
“stem cell genes.” Interestingly, a significant number of these stem
cell-associated genes have also been implicated in tumorigene-
sis and has led investigators to further explore the role of stem
cell-associated genes in malignant cell transformation. In studies
of CSCs, demonstration of stem cell-associated gene expression
has been used as evidence to support the identification of cells
with stem cell-like properties (i.e., putative CSCs) in conjunction
with other cell surface markers or functional assays. However, it
is important to note that expression of any or all of the stem cell-
associated genes is not sufficient for the identification of sarcoma
CSCs as these genes are expressed by normal stem and committed
progenitor cells. It is believed that re-expression of stem cell-
associated genes by cancer cells may simply reflect the malignant
transformation of cells and not necessarily unique to the CSC.
Side population and dye efflux exclusion
One of the characteristic features of CSCs is its inherent or
acquired resistance to cytotoxic chemotherapy agents. One expla-
nation for the relative chemoresistant properties of CSCs involves
the overexpression of ABC (ATP-binding cassette) multidrug
efflux transporters. Capitalizing on this feature of CSCs, several
investigators have utilized a technique involving the use of fluo-
rescent DNA-binding dyes Hoechst 33342 or Rhodamine 123 to
identify putative CSCs through fluorescence-activated cell sorting
(FACS) (Moserle et al., 2008; Fukuda et al., 2009; Song et al., 2010;
Tirino et al., 2012). Expression of ABC transporters on CSCs result
in the active efflux of these fluorescent dyes allowing CSCs to be
identified as a “side population” (SP) of cells by flow cytometry.
Similar to the isolation and characterization of CD133+ cells, SP
cells from a variety of sarcomas have been isolated by FACS and
shown to be capable of initiating tumor formation in immunode-
ficient mice as well as self-renewal properties as evidenced by serial
transplantation experiments (Wu et al., 2007; Tirino et al., 2008;
Murase et al., 2009). In contrast, non-SP cells were generally less
capable of initiating tumors. One drawback of the dye exclusion
technique to identify putative sarcoma CSCs is the inherent tox-
icity associated with the dyes used. Hence, cells with the ability
to efflux the dye have a survival advantage over cells that are less
able to efflux the dye and that the property of dye exclusion may
not necessarily be shared by all sarcoma CSCs. Indeed, non-SP
cells have been evaluated and shown to possess tumor-initiating
and propagating properties including in sarcomas, albeit requiring
larger quantities of tumor inocula, suggesting that dye exclusion
is not an essential feature of sarcoma CSCs and that use of this
technique for the isolation and characterization of sarcoma CSCs
be done only in conjunction with other techniques and/or CSC-
specific markers (Machalinski et al., 1998; Wu et al., 2007; Broadley
et al., 2011).
Aldehyde dehydrogenase
Chemotherapy resistance, as previously mentioned, is a charac-
teristic feature of CSCs. In addition to the overexpression of
drug efflux transporters, CSCs can also upregulate the expres-
sion of detoxification enzymes as an alternative mechanism for
chemotherapy resistance. Aldehyde dehydrogenase (ALDH) cat-
alyzes the oxidation of intracellular aldehydes and biogenic amines
and has also been described to play an important role in drug
detoxification in a variety of normal and malignant cells. Work in
leukemia cells lines, as well as in normal hematopoietic and neural
stem progenitor cells, have revealed significant expression of
ALDH up to 200-fold (Russo and Hilton, 1988; Chute et al., 2006).
In addition to its detoxifying effects, ALDH may also be involved
in regulating stem cell differentiation in hematopoietic stem cells
through retinoid-mediated signaling (Muramoto et al., 2010).
Since progenitor stem cells can be characterized by elevated
intracellular ALDH activity, investigators have examined if high
ALDH activity could identify CSC populations (Awad et al., 2010;
Ma and Allan, 2011). High levels of ALDH activity are indeed
observed in CSC subpopulations in several solid tumors includ-
ing breast, lung, liver, colon, as well as sarcomas. The fluores-
cent reagent (ALDEFLUOR®) commonly utilized in identifying
ALDHHigh cell sub-populations functions primarily as a substrate
for the ALDH 1A1 and 3A1 isoforms. It remains to be determined if
other ALDH isoforms are equally present and expressed in sarcoma
CSCs and if alternate ALDH isoforms can be measured utilizing
this technique.
FUNCTIONAL CANCER STEM CELL ASSAYS
Serial transplantation
The CSC is defined by its capacity to self-renew through symmet-
ric division and recapitulate the heterogeneous lineages of cells
through asymmetric cell division to yield more differentiated cells
that characterize a given tumor. Given this definition of the CSC,
the identification of a CSC relies on a functional assay whereby a
candidate CSC is able to generate a tumor with the same heteroge-
neous cellular constituents of the original tumor from which the
CSC was originally isolated. The tumor initiating and propagating
properties of putative CSCs can be accomplished through serial
transplantation of cells in immunodeficient mice – the current
gold standard used in the identification and characterization of
candidate CSCs.
In general, serial transplantation experiments involve the iso-
lation of candidate CSCs through the use of selective molecular
markers, followed by the subcutaneous or intravenous injection
of cancer cells into immunodeficient mice (Baiocchi et al., 2010;
Tirino et al., 2012). If the inoculated cells are able to give rise to
tumors reminiscent of the parental tumor phenotype, the inoc-
ulated cells are then believed to contain CSCs. In comparison to
non-selected cell populations or cell populations not positive for
the cell marker of interest, the CSC cell population often require
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significantly lower cell inocula to initiate tumor formation in
immunodeficient mice. However, there is currently no standard
as to what strain of immunodeficient mouse to use for serial
transplantation experiments. This point is of importance as the
immune status of recipient mice have been shown to be impor-
tant for the propagation of certain tumors (Chang et al., 2001;
Quintana et al., 2008).
Sphere-formation assay
The ability of cells to form spherical colonies when grown under
non-adherent conditions has been used to identify tissue stem cells
and consequently CSCs. The ability of tissue stem cells and CSCs
to form spheres was first described from studies involving the
identification of neural stem cells which formed free-floating neu-
rospheres after dissociation of brain tissue and culture in serum-
free medium containing epidermal growth factor (Reynolds and
Weiss, 1992; Pastrana et al., 2011). Similar techniques have been
employed in the propagation of CSCs involving the growth of
single cell suspensions of sarcoma cells grown in serum-free con-
ditions to ultimately yield sarcospheres (Gibbs et al., 2005; Fujii
et al., 2009; Tirino et al., 2011). However, sphere formation has
also been shown to arise from non-stem cell populations (Pastrana
et al., 2011). Hence, the ability to form spheres in culture may not
necessarily identify sarcoma CSCs but rather reflect the response
of cells when removed from their normal tissue microenviron-
ment or niche. Furthermore, sphere-formation assays may fail to
identify quiescent CSCs as the success of sphere-formation relies
on an expanding cell population that is either poised to proliferate
or are actively dividing.
SARCOMA STEM CELLS
The identification and characterization of CSCs from malignant
solid tumors, such as breast, skin, brain, or colon, have prompted
the search for this elusive population of cells in sarcomas. Adopting
the techniques just described and developed in the investigation
of normal and malignant stem cells, we now examine the current
evidence suggesting the existence of CSCs in sarcomas.
OSTEOSARCOMA
Osteosarcomas comprise the most common malignant tumor of
bone in children and adolescents. Therapy incorporating multi-
agent cytotoxic chemotherapy and surgery has resulted in cure
rates of 60–70% in the localized disease setting (Bacci et al., 1993).
However,∼15% of patients present with disseminated or metasta-
tic disease at initial presentation and have poor survival rates of
<20% despite aggressive multi-modal therapy (Harris et al., 1998).
Given that one of feature of a CSC is its inherent resistance to
cytotoxic chemotherapy drugs, the identification and direct target-
ing of sarcoma CSCs in osteosarcoma may improve the survival
outcomes for all osteosarcoma patients, particularly those with
metastatic disease.
One of the first reports of cells derived from osteosarcoma with
stem cell-like properties was a study by Tsuchida et al. (2008) who
showed that a SP of cells could be isolated by exposure of the
HOS osteosarcoma cell line to the chemotherapy agent cisplatin.
Although the cisplatin-treated SP cells demonstrated several CSC
features including expression of stem cell-associated genes, colony
growth, and tumor formation, SP cells from untreated cells failed
to form tumors suggesting that the SP population in treated cells
may have undergone clonal selection and enrichment for cells
with increased tumorigenicity, but not necessarily identification
of a sarcoma CSC.
A subsequent study by Tirino et al. (2008) evaluated the utility
of CD133 expression to identify and isolate a subpopulation of
cells with CSC properties in osteosarcoma cell lines. Examination
of osteosarcoma cell lines identified a subpopulation of CD133+
cells which exhibited self-renewal properties, higher proliferative
rates, spherical colony formation, and expression of the stem cell-
associated gene OCT3/4. However, the tumorigenic potential of
CD133+ population was not evaluated through in vivo xenotrans-
plant assays. A follow-up study by the same group evaluated 21
patient-derived sarcoma tissues which showed variable expression
of CD133 (Tirino et al., 2011). Relatively high CD133 expres-
sion was observed in 2 osteosarcoma tissues examined which
were successfully maintained in in vitro cell culture. However,
the CD133+ fraction from both osteosarcoma cell lines were
incapable of tumor formation when injected into non-obese dia-
betic (NOD)/severe combined immunodeficiency (SCID) mice
which leads one to question the validity of CD133 expression in
identifying a tumorigenic CSC population in osteosarcoma.
Other cell surface markers have been identified which appear to
more selectively enrich for cells with tumor-initiating properties.
Adhikari and colleagues examined the expression of two mes-
enchymal stem cell markers, CD117 and Stro-1, and discovered
that mouse and human osteosarcoma cell lines positive for both
CD117 and Stro-1 (DP or double positive cells) readily formed
spherical colonies, more readily formed tumors in a nude mouse
model in comparison to cells negative for both CD117 and Stro-
1 (DN or double negative cells), had higher metastatic potential
in an orthotopic NOD/SCID mouse model, exhibited increased
chemoresistance when exposed to the chemotherapy agent dox-
orubicin, retained multipotent differentiation ability, and able to
reconstitute DP and DN populations upon serial transplantation
(Adhikari et al., 2010). This study has been the first to specifically
identify a subpopulation of osteosarcoma cells with the hallmark
features of a CSC: self-renewal capacity and the ability to recon-
stitute the original cellular makeup of a tumor or cell population
upon serial transplantation. Validation of the stem cell-like prop-
erties of the DP population of cells in a broader panel of primary,
patient-derived osteosarcoma cells would further strengthen the
utility of CD117 and Stro-1 marker expression as specific markers
for the identification, isolation, and therapeutic targeting of this
unique population in osteosarcoma.
Analysis of SP cells, for the presence of sarcoma CSCs have
also yielded cells exhibiting stem cell features. Murase et al. (2009)
examined osteosarcoma cell lines and a malignant fibrous his-
tiocytoma cell line and found that the MFH and only one of
seven osteosarcoma cell lines had an identifiable SP fraction.
Moreover, only the SP cells derived from the MFH cell line was
able to form tumors in NOD/SCID mice, whereas SP cells from
the osteosarcoma cell line could not. Interestingly, it has been
recently shown that blockade of developmentally important sig-
naling pathways, specifically hedgehog and Notch, in the MFH
SP fraction abrogated its proliferative and tumorigenic capacities
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potentially implicating these pathways in the process of stem cell
renewal and presenting a rationale for future therapeutic targeting
(Wang et al., 2012). In contrast, Yang et al. (2010) derived SP cells
from primary osteosarcoma cell lines and found that SP, as well
as non-SP cells, were capable of tumor formation thus question-
ing the validity of SP cells as a specific CSC marker. These results
underscore the importance of utilizing alternative assays and cell
surface markers for the identification and isolation of putative sar-
coma CSCs as SP-based isolation does not appear to be sufficient
and selective for the enrichment of sarcoma CSCs. A lack of spe-
cific criteria and guidelines for the delineation of the SP fraction
has likely contributed in the disparate results described. Alterna-
tively, the inconsistent results from studies evaluating the SP cell
fraction or various candidate CSC cell surface markers may reflect
the cellular heterogeneity of osteosarcoma tumors. Furthermore,
the identity of the CSC fraction in osteosarcoma may consist of a
dynamic population of cells that may modulate its immunophe-
notype in response to microenvironmental cues and, thus, differ
among cell lines and patients – a phenomenon described in other
solid tumors (Quintana et al., 2010; Chaffer et al., 2011; Gupta
et al., 2011). The ability to track individual cells within the tumor
bulk may help to clarify these issues and help to identify CSCs in
osteosarcoma.
Lineage tracking of cells offers a novel means by which to
identify and subsequently follow the fate of candidate CSCs. Lev-
ings et al. (2009) generated a transgenic osteosarcoma cell line
expressing a green fluorescent protein (GFP) reporter gene under
the control of the stem cell-associated gene OCT-4. Subsequent
enrichment of GFP+ cells yielded a population with increased
tumor formation and metastatic capacity compared to GFP-
depleted cells, and gave rise to heterogeneous tumors suggestive.
However, it is noteworthy to mention that GFP-depleted cell pop-
ulations were also capable of forming tumors in NOD/SCID mice
albeit at higher concentrations. Nevertheless, genetic lineage track-
ing of cells would be an extremely valuable tool for the prospective
identification and tracking of candidate sarcoma CSCs during its
evaluation for stem cell properties.
Observations of elevated ALDH activity in normal tissue stem
cells, as well as in hematopoietic and solid tumor CSCs, have led
to the use of ALDH activity as a means of identifying CSC popula-
tions in sarcomas. Wang et al. (2011b) examined osteosarcoma cell
lines and found that all cell lines contained a sub population of cells
with high ALDH activity (ALDHBr) and which possessed increased
tumorigenic capacity compared to ALDHLow cells, increased pro-
liferative and clonogenic abilities, showed increased expression of
stem cell markers, and self-renewal capacity. In contrast,ALDHLow
cells were incapable of forming tumors in NOD/SCID mice.
In a follow-up study, pre-treatment of ALDHBr cells with bone
morphogenetic protein-2 (BMP-2), which belong to a class of
molecules known to be important in bone and cartilage for-
mation, can effectively inhibit the tumor-initiating properties of
ALDHBr cells (Wang et al., 2011a). These results support the use
of ALDHBr selection to identify and isolate a sarcoma CSC-like
population from osteosarcoma cells and illustrate the potential
utility of CSC-based research in identifying novel therapeutic tar-
gets (e.g., BMP-2 signaling pathway). However, in a similar study
evaluating the ALDHBr cells derived from the osteosarcoma cell
line MG63, ALDHBr as well as ALDHLow cells equally showed the
ability to reconstitute the original whole cell population putting
into question the validity of ALDH activity as a specific sarcoma
CSC marker (Honoki et al., 2010). Further testing in a broader
panel of cell lines and primary tumors may clarify this issue. Addi-
tionally, the arbitrary cutoff for high and low ALDH expression
may also contribute to differing results. Thus, similar to the issue
with using SP as a means of identifying CSC populations, con-
sensus definitions for these assays will be essential for acquiring
consistent experimental outcomes and effective translation of data
among different investigators.
EWING SARCOMA
Ewing sarcoma is the second most common malignant tumor of
bone and soft tissue in children and young adults. Ewing sar-
coma comprises a group of tumors with a spectrum of phenotypic
and clinical manifestations and is characterized by the presence of
unique fusion oncoproteins which join the EWSR1 gene with sev-
eral members of the ETS family of transcription factors, most
commonly FLI-1 (∼80% of clinical cases) (Balamuth and Womer,
2010). Although the exact functions of these fusion oncoproteins
remain to be more clearly elucidated, expression of the fusion
oncogenes is essential to the oncogenic phenotype of Ewing sar-
coma as well as in the regulation of genes involved in metastasis
and chemoresistance (May et al., 1993; Lessnick et al., 1995; Denny,
1996; Thompson et al., 1999; Arvand and Denny, 2001). Similar
to osteosarcomas, survival in the metastatic or recurrent disease
setting remain abysmally low at<20%. If sarcoma CSCs do indeed
exist for Ewing sarcoma and are responsible for the resistance to
conventional chemotherapeutic interventions, the identification
and selective targeting of the CSC subpopulation will be essential
in securing durable curative responses.
Similar in approach to the identification of CSC subpopula-
tions in osteosarcoma cells, Suva et al. (2009) were the first to
report on the isolation of CD133+ cells derived from primary
Ewing sarcoma tumors. They showed that CD133+ cells were
capable of initiating and forming tumors in NOD/SCID mice
and were capable of recapitulating the parental tumor phenotype
upon serial transplantation in NOD/SCID mice. Furthermore,
only the CD133+ subpopulation could renew both CD133+ and
CD133− cell populations. In a subsequent study by the same
group, Riggi et al. (2010) expressed the characteristic Ewing sar-
coma fusion oncogene EWS/FLI-1 in undifferentiated human
MSCs (hMSCEWS/FLI-1) derived from pediatric bone marrow sam-
ples and demonstrated the generation of a CD133+ subpopulation
of cells with stem cell properties. However, CD133+ cells derived
from hMSCEWS/FLI-1 were unable to form tumors in NOD/SCID
mice suggesting that EWS/FLI-1 expression in human MSCs is
insufficient for tumorigenesis and despite the change in phenotype
reminiscent of stem-like cells.
In contrast to the previously described work, Jiang et al. (2010)
found heterogeneous expression of CD133 in 48 primary Ewing
sarcoma tumors examined. Only 4 of the 48 Ewing sarcoma tumors
exhibited high expression of CD133, and this heterogeneity in
CD133 expression was similarly observed in nine Ewing sarcoma
cell lines studied. With the exception of one cell line, STA-ET-
8.2, no differences in chemoresistance or tumorigenic potential
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was observed between CD133+ and CD133− subpopulations.
Thus, the significance of CD133+ in identifying a CSC popu-
lation in Ewing sarcoma remains to be seen. Wahl et al. (2010)
demonstrated that Ewing sarcoma cells expressing the neural crest
marker CD57 (HNK-1) identified a population of highly tumori-
genic cells with features of a CSC including self-renewal abilities
on repeat serial transplantation and multipotent differentiation
capacity in the CD57High cell fraction. Interestingly, the tumori-
genic CD57High fraction did not consistently correlate with the
coexpression of CD133 and CD57High cells absent CD133 expres-
sion were highly tumorigenic suggesting that other cell surface
markers can similarly be utilized to identify cells with CSC prop-
erties. It is important to point out that CD57Low cells were also
capable of inducing tumor formation and maintain this ability
with serial transplantation, albeit at a much lower capacity, pre-
cluding the use of cell surface markers such as CD57 or CD133 in
identifying the stem cell population in Ewing sarcoma.
The utility of SP cells in identifying stem-like cells in Ewing
sarcoma has also been explored. Yang et al. (2010) isolated the SP
fraction from the Ewing sarcoma cell line SK-ES-1 and showed
that the SP cells can give rise to both SP and non-SP cells. SP
cells also exhibited increased clonogenicity, invasive behavior, and
cytotoxic drug resistance when compared to parental and non-
SP cells. However, the ability of the SP population to propagate
tumors in vivo was not performed. SP cells have also been observed
in other Ewing sarcoma cell lines (Komuro et al., 2007), but
prospective validation of this cell population through serial trans-
plantation experiments would need to be performed to determine
the presence of putative sarcoma CSCs.
Isolation of cells with high ALDH activity has also shown
promise in identifying cell populations in Ewing sarcoma enriched
for cells with potent tumor-initiating ability. Awad et al. (2010)
examined Ewing sarcoma cell lines and patient-derived Ewing sar-
coma xenograft tumors and defined an ALDHHigh and ALDHLow
population (defined as cells with the highest and lowest 2% ALDH
activity). Cells from the ALDHHigh sub-population demonstrated
CSC properties and were highly tumorigenic. ALDHHigh cells were
also more resistant to the cytotoxic effects of chemotherapy drugs.
Interestingly, a selective inhibitor of EWS/FLI-1 (YK-4-279) was
effective in inhibiting the growth and tumorigenic capacity of both
ALDHHigh and ALDHLow cells indicating the dependence of the
ALDHHigh population on EWS/FLI-1 oncogene expression (Awad
et al., 2010). Furthermore, the investigators compared the clono-
genic and tumorigenic properties of ALDHHigh cells compared to
a cell population enriched for CD133+ cells and demonstrated
superior colony formation and tumor induction when using cells
derived from the ALDHHigh fraction suggesting superior enrich-
ment of putative CSCs using the ALDEFLUOR-based assay. How-
ever, as previously mentioned, the delimitation of ALDHHigh or SP
fractions are arbitrary and differ among investigators, and this lack
of specific consensus and guidelines will hinder the prospective
analysis of data utilizing these techniques.
RHABDOMYOSARCOMA
Rhabdomyosarcoma (RMS) is the most common soft tissue sar-
coma and the third most common extracranial solid tumor
encountered in children while being exceedingly rare in adults.
Similar to Ewing sarcoma, ∼20–30% of RMS cases involve
the presence characteristic chromosomal translocations result-
ing in the production of an aberrant fusion oncogene. The
PAX3/FOXO1 (previously designated PAX3/FKHR) and the less
common PAX7/FOXO1 have classically characterized a more clin-
ically aggressive subset of RMS referred to as the alveolar variant.
The more common embryonal RMS variant is not associated with
any characteristic cytogenetic abnormalities and tends to have a
more favorable prognosis. Also similar to both osteosarcomas and
Ewing sarcoma, RMS involves multi-modality treatment with gen-
erally favorable survival outcomes in the localized disease setting
(∼70–80% survival) and poor outcomes for metastatic disease
(∼20% survival).
There remains little published work regarding the determi-
nation of a CSC-like population in RMS. Komuro et al. (2007)
showed that RMS, along with Ewing sarcoma and neuroblas-
toma cells possessed a SP of cells based on Hoechst 33342 dye
exclusion. More recently, Walter et al. (2011) generated spher-
ical colonies (termed rhabdospheres) from five RMS cell lines
and demonstrated that these cells possessed stem cell proper-
ties including elevated expression of stem cell markers (OCT-4,
NANOG, c-MYC, SOX2, and PAX3) and formed tumors at lower
cell densities compared to adherent cells. The investigators fur-
ther sorted the cells derived from spherical colonies and isolated a
CD133+ cell fraction. The CD133+ cells, in contrast to CD133−
and unsorted cells, were able to generate tumors in NOD/SCID
mice at lower cell densities and were more resistant to treat-
ment with the chemotherapy drugs cisplatin and chlorambucil.
Furthermore, analysis of CD133+ expression in patient-derived
tissue samples revealed that high CD133+ expression correlated
with inferior survival compared to low or intermediate expres-
sion levels in patients with the embryonal RMS variant. Hence,
CD133 expression in RMS may not only be useful in enriching
for candidate sarcoma CSCs, but may also have clinical utility
in predicting survival outcomes. It remains to be seen if selec-
tion based on ALDH activity, perhaps in conjunction with CD133
expression, would further enrich for cells with stem cell-like
properties.
OTHER SOFT TISSUE SARCOMAS
Given the identification and isolation of cells with stem cell-like
properties in osteosarcoma, Ewing sarcoma, and RMS, there has
been increased interest in the search for similar stem-like cells in
other sarcoma subtypes. Stratford et al. (2011) have identified can-
didate sarcoma CSCs in a liposarcoma cell line (SW872) after dou-
ble enrichment for CD133 and ALDHHigh activity (ALDHHigh).
Cells doubly positive for CD133 and ALDHHigh were more clono-
genic and tumorigenic when compared to parental cells or cells
singly positive for either CD133 or ALDHHigh. Similarly, chon-
drosarcoma cells derived from primary tumors and enriched for
CD133 also showed potent tumorigenic potential (Tirino et al.,
2011). Synovial sarcoma tumors and cell lines also express CD133,
though it remains to be shown whether these cells possess stem
cell-like properties and are tumorigenic (Terry and Nielsen, 2010).
However, a SP of cells derived from a primary synovial sar-
coma tumor, as well as from other mesenchymal solid tumors
(e.g., malignant fibrous histiocytoma) were capable of forming
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tumors in NOD/SCID mice in one investigation (Wu et al., 2007).
However, it is unclear if the SP cells isolated in the latter study
necessarily represent a population of cells with CSC properties or
cells selected for heightened proliferative and tumorigenic capacity
since SP and non-SP cells formed tumors.
CONCLUSION
The search for the elusive CSC in sarcomas and other solid tumors
remains a challenging and controversial area of research. The
immense clinical and biological diversity of sarcomas add to the
difficulties in performing research within this family of malig-
nant tumors. Additionally, if one considers that the search for the
sarcoma CSC involves a search for cells that may exhibit vary-
ing degrees of “stemness” dependent upon microenvironmental
cues as recent research suggests (Chaffer et al., 2011), the chal-
lenge of CSC research in sarcomas appears daunting given current
technologies.
Work in normal tissue stem cells and CSCs derived from other
solid tumors have expanded our current understanding of both
normal and malignant stem cell biology and have led to the
development of novel techniques to identify and study the CSC
population within a heterogeneous tumor. In this review, we have
discussed the data with regards to the promise of cell surface
markers such as CD133, CD117, or Stro-1 in the identification
of candidate sarcoma CSCs. Refinements in flow cytometric tech-
niques have allowed for the identification of SPs of cells which
exhibit stem cell-like properties including self-renewal, tumor ini-
tiation and serial propagation, and inherent resistance to cytotoxic
chemotherapy agents. At the very least, the techniques and assays
described have allowed for the isolation of cell populations that
contain within it the ever elusive CSC. Further technical refine-
ments and use of novel techniques such as genetic lineage tracking
may someday allow for the identification and isolation of a more
pure population of CSCs from sarcomas – a goal yet to be achieved.
In light of recent work suggesting the ability of a CSC to intercon-
vert between tumorigenic and non-tumorigenic states depending
upon tumor microenvironmental cues (Quintana et al., 2008;
Chaffer et al., 2011), improved understanding into the cell origins
of sarcomas and further refinements in the molecular characteri-
zation of sarcoma subtypes will be essential in the discrimination
of putative CSCs contained within any given tumor. Furthermore,
establishment of consensus definitions of what constitutes a CSC
and more defined criteria for the delineation of candidate stem
cells identified via the various assays described above (e.g., SPs,
ALDHHigh/Bright populations) will be paramount to any progress
achieved in the study of stem cell biology. In the future, the
unequivocal identification and validation of the existence of CSCs
in sarcomas, or any other cancer, coupled with the development of
drugs that will specifically target this population, may allow for a
paradigm shift in how we view the evolution of cancers, as well as
how we develop future strategies for effectively eradicating cancers
in children and adults.
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